By Blake Brittain

作者：Blake Brittain

Aug 21 (Reuters) - A Delaware federal jury determined on Friday that Cytek Biosciences’ (CTKB.O) products for analyzing single-cell blood and tissue samples infringe a patent owned by rival Beckman Coulter.

8 月 21 日（路透社）- 特拉華州聯邦陪審團週五裁定，Cytek Biosciences (CTKB.O) 用於分析單細胞血液和組織樣本的產品侵犯了競爭對手貝克曼庫爾特擁有的一項專利。

The jury agreed with Danaher-owned (DHR.N) Beckman that Cytek’s Aurora flow cytometers and other products violate Beckman’s patent rights in technology used in its competing CytoFLEX platform.

陪審團認同丹納赫 (DHR.N) 旗下貝克曼的觀點，即 Cytek 的 Aurora 流式細胞儀及其他產品侵犯了貝克曼在其競爭性平台 CytoFLEX 所用技術方面的專利權。

The jury said that Cytek owed Beckman $36 million in royalties and $20 million in lost profits.

陪審團表示，Cytek 需向貝克曼支付 3,600 萬美元的特許權使用費和 2,000 萬美元的利潤損失。

Spokespeople for the companies did not immediately respond to requests for comment on the verdict.

兩家公司發言人未立即回應置評請求。

Beckman first sued Cytek over the patents in 2024.

貝克曼於 2024 年首次就這些專利起訴 Cytek。

Cytek denied the allegations and argued the patents were invalid.

Cytek 否認了相關指控，並主張這些專利無效。

The jury found on Thursday that Cytek did not infringe two of the three patents at issue in the trial and that those two patents were invalid.

陪審團週四認定，Cytek 並未侵犯庭審中涉及的三項專利中的兩項，且該兩項專利無效。

California-based Cytek earned $201.5 million from overall sales of its products last year, according to a company report.

根據公司報告，總部位於加利福尼亞州的 Cytek 去年產品總銷售額為 2.015 億美元。